AR085149A1 - Moduladores del receptor de glucagon - Google Patents

Moduladores del receptor de glucagon

Info

Publication number
AR085149A1
AR085149A1 ARP120100379A ARP120100379A AR085149A1 AR 085149 A1 AR085149 A1 AR 085149A1 AR P120100379 A ARP120100379 A AR P120100379A AR P120100379 A ARP120100379 A AR P120100379A AR 085149 A1 AR085149 A1 AR 085149A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
fluorine
cycloalkyl
independently
Prior art date
Application number
ARP120100379A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR085149A1 publication Critical patent/AR085149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Electrotherapy Devices (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se ha encontrado que los compuestos de fórmula (1) actúan como antagonistas o agonistas inversos de glucagón. En consecuencia, los compuestos de fórmula (1) y las composiciones farmacéuticas del mismo son útiles para el tratamiento de enfermedades, trastornos o afecciones mediadas por glucagón.Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo; en la que R1 es un grupo heteroarilo de 5 miembros unido a través de bien un átomo de carbono o un átomo de nitrógeno y que está opcionalmente condensado con un cicloalquilo C4-7, un fenilo o un heteroarilo de 6 miembros; estando el heteroarilo de 5 miembros opcionalmente sustituido con uno a cuatro sustituyentes seleccionados cada uno independientemente de entre halo, -S(O)2-alquilo C1-3, -S-alquilo C1-3, hidroxilo, -C(O)NRaRb, cicloalquilo C3-5, ciano, fenilo que está opcionalmente sustituido con uno a tres halo, ciano, alquilo C1-3 o alcoxi C1-3, heteroarilo de 6 miembros que está opcionalmente sustituido con uno a tres halo, ciano, alquilo C1-3 o alcoxi C1-3, alquilo C1-6 opcionalmente sustituido con uno a tres flúor, o alcoxi C1-6 opcionalmente sustituido con uno a tres flúor; Ra y Rb son cada uno independientemente H o alquilo C1-3; R2 es H o metilo; R3 es tetrazolilo, -CH2-tetrazolilo, -(CH2)2SO3H o -(CH2)2CO2H, -CH2CHFCO2H o -CH2CHOHCO2H; A1, A2, A3 y A4 son cada uno independientemente CR4 o N, con la condición de que no más de dos de entre A1, A2, A3 y A4 sean N; R4 en cada aparición es independientemente H, halo, ciano, alquilo C1-3 opcionalmente sustituido con uno a tres flúor, o alcoxi C1-3 opcionalmente sustituido con uno a tres flúor; L es -X-CH(R5)- o -CH(R5)-X-; X es CH2, O o NH; R5 es alquilo C1-6 que está opcionalmente sustituido con uno a tres flúor, hidroxilo o metoxi; cicloalquilo C3-7 que está opcionalmente sustituido con uno a dos alquilo C1-3 que están opcionalmente sustituidos con uno a tres flúor y pudiendo estar reemplazados uno a dos carbonos del cicloalquilo C3-7 por un NH, N-alquilo C1-3, O ó S; o cicloalquil C3-7-alquilo C1-6, en el que el grupo cicloalquilo C3-7 de dicho cicloalquil C3-7-alquilo C1-6 está opcionalmente sustituido con uno a dos alquilo C1-3 que están opcionalmente sustituidos con uno a tres flúor; B1, B2, B3 y B4 son cada uno independientemente CR6 o N, con la condición de que no más de dos de B1, B2, B3 y B4 sean N; y R6 en cada aparición es independientemente H, halo, alquilo C1-3 opcionalmente sustituidos con uno a tres flúor, o alcoxi C1-3 opcionalmente sustituido con uno a tres flúor.
ARP120100379A 2011-02-08 2012-02-06 Moduladores del receptor de glucagon AR085149A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440578P 2011-02-08 2011-02-08
US201161441044P 2011-02-09 2011-02-09
US201261585834P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
AR085149A1 true AR085149A1 (es) 2013-09-11

Family

ID=45607316

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100379A AR085149A1 (es) 2011-02-08 2012-02-06 Moduladores del receptor de glucagon

Country Status (38)

Country Link
US (5) US8507533B2 (es)
EP (1) EP2673260B1 (es)
JP (1) JP5562495B2 (es)
KR (2) KR101585840B1 (es)
CN (2) CN103370306B (es)
AP (1) AP3338A (es)
AR (1) AR085149A1 (es)
AU (1) AU2012215114B2 (es)
BR (1) BR112013020035A2 (es)
CA (1) CA2825102C (es)
CL (1) CL2013002053A1 (es)
CO (1) CO6741217A2 (es)
CR (1) CR20130372A (es)
CY (1) CY1118039T1 (es)
DK (1) DK2673260T3 (es)
DO (1) DOP2013000181A (es)
EA (1) EA023517B1 (es)
EC (1) ECSP13012871A (es)
ES (1) ES2597972T3 (es)
GE (1) GEP20156351B (es)
GT (1) GT201300196A (es)
HK (2) HK1188992A1 (es)
HR (1) HRP20161177T1 (es)
HU (1) HUE030364T2 (es)
IL (1) IL227559A (es)
LT (1) LT2673260T (es)
ME (1) ME02502B (es)
MX (1) MX2013009140A (es)
NI (1) NI201300068A (es)
PE (1) PE20140253A1 (es)
PT (1) PT2673260T (es)
RS (1) RS55225B1 (es)
SG (1) SG192004A1 (es)
SI (1) SI2673260T1 (es)
TW (3) TW201540710A (es)
UY (1) UY33896A (es)
WO (1) WO2012107850A1 (es)
ZA (1) ZA201306310B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL227559A (en) * 2011-02-08 2016-04-21 Pfizer Glucagon receptor modulator
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2832725A4 (en) 2012-03-29 2015-11-25 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
MX2015014407A (es) 2013-04-15 2015-12-07 Du Pont Amidas fungicidas.
CN107235960B (zh) * 2016-03-29 2021-01-29 浙江海正药业股份有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
DK3573611T3 (da) * 2017-01-24 2022-04-11 Alphala Co Ltd Amidforbindelser og anvendelse deraf
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IL270068B (en) 2017-04-24 2022-06-01 Tesaro Inc Manufacturing methods of Niraprib
CA3089374A1 (en) * 2018-02-28 2019-09-06 Basf Se Use of alkoxypyrazoles as nitrification inhibitors
WO2019224139A1 (de) * 2018-05-24 2019-11-28 Bayer Aktiengesellschaft Verfahren zur herstellung von halogenierten n-arylpyrazolen
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
BR112022006977A2 (pt) 2019-10-11 2022-09-20 Incyte Corp Aminas bicíclicas como inibidores de cdk2
MX2022011025A (es) * 2020-03-06 2022-10-07 Alphala Co Ltd Procesos para producir compuestos de amida, y su forma cristalina y de sal.
CN111793033A (zh) * 2020-08-10 2020-10-20 成都正善达生物医药科技有限公司 一种普那布林中间体咪唑甲醛类化合物的制备方法
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320825A (en) 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1994014427A2 (en) 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
ATE189217T1 (de) 1993-03-19 2000-02-15 Merck & Co Inc Phenoxyphenylessigsäurederivate
GB9408185D0 (en) 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE4426346A1 (de) 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0859771A4 (en) 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHOD OF USE
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271893A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles as glucagon antagonists
US5880139A (en) 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
PL334059A1 (en) 1996-12-11 2000-01-31 Basf Ag Ketone benzamides useful as calpain inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1042293B9 (en) 1997-12-19 2008-09-03 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
DE60035682T2 (de) 1999-04-28 2008-04-30 Sanofi-Aventis Deutschland Gmbh Di-aryl-säurederivate als ppar rezeptor liganden
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
ES2250128T3 (es) 1999-05-17 2006-04-16 Novo Nordisk A/S Antagonistas/agonistas inversos de glucagon.
CN1437581A (zh) 2000-06-23 2003-08-20 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
EP1345891A1 (en) 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon antagonist/inverse agonist
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
GEP20053710B (en) 2001-02-28 2005-12-26 Merck & Co Inc Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
WO2003047626A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
KR20090083491A (ko) 2002-02-01 2009-08-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 ２－퓨란 카르복시산 하이드라지드 화합물 및 그것을 함유하는 의약 조성물
MXPA04009040A (es) 2002-03-20 2005-01-25 Metabolex Inc Acidos fenilaceticos sustituidos.
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
AU2003268529B2 (en) 2002-09-12 2007-08-09 Merck & Co., Inc. Method of treating diabetes and related conditions
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US20040097557A1 (en) 2002-11-13 2004-05-20 Duffy Joseph L. Cyanothiophene derivatives, compositions containing such compounds and methods of use
CA2508581A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
US20040209928A1 (en) 2002-12-30 2004-10-21 Ravi Kurukulasuriya Glucagon receptor antagonists/inverse agonists
DE10300398A1 (de) 2003-01-09 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel
US7151114B2 (en) 2003-01-09 2006-12-19 Boehringer Ingelheim International Gmbh Use of substituted 2-phenylbenzimidazoles as medicaments
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
ATE490244T1 (de) 2003-01-27 2010-12-15 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
DE602004011511T2 (de) 2003-04-14 2009-01-29 The Institutes for Pharmaceutical Discovery, LLC, Branford N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
AU2004236248A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids
EP1626717A4 (en) 2003-05-09 2009-09-09 Merck & Co Inc BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
US7355049B2 (en) 2003-06-24 2008-04-08 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activator
JP4412098B2 (ja) 2003-07-31 2010-02-10 Ｊｆｅスチール株式会社 溶接熱影響部靭性に優れた低降伏比高強度鋼板及びその製造方法
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005058845A2 (en) 2003-12-19 2005-06-30 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
JP2007514794A (ja) 2003-12-19 2007-06-07 メルク　エンド　カムパニー　インコーポレーテッド 環式グアニジン、そのような化合物を含む組成、及び使用方法
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
US7989457B2 (en) * 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
PL1758853T3 (pl) 2004-06-14 2010-06-30 Lilly Co Eli Antagoniści receptora glukagonu, wytwarzanie i zastosowania terapeutyczne
WO2006017055A2 (en) 2004-07-07 2006-02-16 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
CN1993124A (zh) 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
DE102004051188A1 (de) 2004-10-21 2006-04-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cyanothiophene, deren Herstellung und deren Verwendung als Arzneimittel
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20070104409A (ko) 2005-02-11 2007-10-25 일라이 릴리 앤드 캄파니 글루카곤 수용체 길항제로서의 치환된 티오펜 유도체, 제법및 치료 용도
CA2600159A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CA2600833A1 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
BRPI0616960B8 (pt) 2005-10-06 2021-05-25 Probi Ab uso de lactobacilo para o tratamento de infecções virais
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EP2298308B1 (en) 2005-11-14 2013-01-16 University Of Southern California Integrin-binding small molecules
JP5198280B2 (ja) * 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
ES2391109T3 (es) 2005-11-17 2012-11-21 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
AU2006341392B2 (en) * 2005-11-18 2012-05-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618140A2 (pt) * 2005-11-22 2011-08-16 Lilly Co Eli composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou um sal do mesmo
CA2629311C (en) 2005-11-23 2014-05-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
AU2006327892B2 (en) 2005-12-19 2011-12-22 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
EP2001472A2 (en) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR101538810B1 (ko) 2007-02-09 2015-07-22 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
JP2009040702A (ja) 2007-08-07 2009-02-26 Daiichi Sankyo Co Ltd 新規アミドプロピオン酸誘導体を含有する医薬組成物
US8232413B2 (en) 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
JP5450083B2 (ja) 2007-11-01 2014-03-26 武田薬品工業株式会社 複素環化合物
ES2382579T3 (es) 2007-12-11 2012-06-11 Cadila Healthcare Limited Peptidomiméticos con actividad antagonista de glucagón y agonista de GLP-1
MY158982A (en) 2008-03-05 2016-11-30 Takeda Pharmaceuticals Co Heterocyclic compound
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
CA2724294A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
CA2770298C (en) 2008-08-13 2017-06-20 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010019828A1 (en) 2008-08-13 2010-02-18 Metabasis Therapeutics, Inc. Glucagon receptor antagonists
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN102459215B (zh) 2009-05-14 2016-03-02 大日本住友制药株式会社 3-(4-氨基苯基)-2-呋喃甲酸衍生物及其药学上可接受的盐
WO2010144664A1 (en) 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
WO2011027849A1 (ja) 2009-09-04 2011-03-10 武田薬品工業株式会社 複素環化合物
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
CA2794003A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
AU2011232657A1 (en) 2010-03-26 2012-09-27 Merck Sharp & Dohme Corp. Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
IL227559A (en) * 2011-02-08 2016-04-21 Pfizer Glucagon receptor modulator

Also Published As

Publication number Publication date
PT2673260T (pt) 2016-10-24
IL227559A0 (en) 2013-09-30
CN103370306B (zh) 2015-12-02
GT201300196A (es) 2014-06-06
CL2013002053A1 (es) 2013-11-29
NZ613269A (en) 2014-06-27
DOP2013000181A (es) 2013-09-30
EP2673260A1 (en) 2013-12-18
US20150266859A1 (en) 2015-09-24
BR112013020035A2 (pt) 2016-07-19
ME02502B (me) 2017-02-20
US20130296355A1 (en) 2013-11-07
AP3338A (en) 2015-07-31
US8859591B2 (en) 2014-10-14
TWI490202B (zh) 2015-07-01
US20160362392A1 (en) 2016-12-15
CY1118039T1 (el) 2017-05-17
CA2825102C (en) 2016-03-08
CN104744370A (zh) 2015-07-01
HUE030364T2 (hu) 2017-04-28
US20120202834A1 (en) 2012-08-09
TW201540710A (zh) 2015-11-01
JP5562495B2 (ja) 2014-07-30
SG192004A1 (en) 2013-08-30
AU2012215114A1 (en) 2013-08-01
UY33896A (es) 2012-09-28
KR101585840B1 (ko) 2016-01-15
KR101638671B1 (ko) 2016-07-11
JP2014504631A (ja) 2014-02-24
HRP20161177T1 (hr) 2016-11-04
HK1188992A1 (zh) 2014-05-23
US8507533B2 (en) 2013-08-13
CA2825102A1 (en) 2012-08-16
EP2673260B1 (en) 2016-08-17
ZA201306310B (en) 2014-04-30
PE20140253A1 (es) 2014-03-09
KR20130118385A (ko) 2013-10-29
SI2673260T1 (sl) 2016-10-28
CO6741217A2 (es) 2013-08-30
EA201390969A1 (ru) 2013-12-30
EA023517B1 (ru) 2016-06-30
TW201245146A (en) 2012-11-16
TW201429947A (zh) 2014-08-01
CN103370306A (zh) 2013-10-23
AP2013007012A0 (en) 2013-07-31
ES2597972T3 (es) 2017-01-24
CR20130372A (es) 2013-09-18
KR20150038705A (ko) 2015-04-08
RS55225B1 (sr) 2017-02-28
DK2673260T3 (en) 2016-10-10
NI201300068A (es) 2013-12-11
ECSP13012871A (es) 2013-10-31
IL227559A (en) 2016-04-21
US9073871B2 (en) 2015-07-07
HK1207858A1 (en) 2016-02-12
MX2013009140A (es) 2013-10-01
LT2673260T (lt) 2016-10-25
US20140371467A1 (en) 2014-12-18
AU2012215114B2 (en) 2016-05-12
US9452999B2 (en) 2016-09-27
WO2012107850A1 (en) 2012-08-16
GEP20156351B (en) 2015-08-25

Similar Documents

Publication Publication Date Title
AR085149A1 (es) Moduladores del receptor de glucagon
AR081390A1 (es) Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra)
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20190710A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
PE20091100A1 (es) Nuevos compuestos 010
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ES2569539T3 (es) Derivados de piperidin-4-il azetidina como inhibidores de JAK1
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
AR084579A1 (es) Moduladores del receptor de glucagon
MY170822A (en) Ethynyl derivatives as mglur5 allosteric modulators
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
CO6801735A2 (es) Derivados de pirazolidin-3-ona
AR084916A1 (es) Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas
AR075032A1 (es) Pirazinonas sustituidas
MX2019000361A (es) Moduladores heteroaromaticos del receptor huerfano relacionado con retinoide gamma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure